Meropenem Hikma (Meropenem)

Meropenem Hikma is a carbapenem antibiotic used to treat severe bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: eradicates causative pathogens and supports clinical recovery.
• Complicated urinary tract infections: eliminates resistant Gram‑negative organisms and improves urinary tract health.
• Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.
• Severe skin and soft‑tissue infections: provides broad coverage against resistant skin pathogens.
• Hospital‑acquired pneumonia: targets multidrug‑resistant respiratory bacteria.
• Sepsis: delivers rapid bactericidal activity in systemic infections.

• Meropenem inhibits bacterial cell wall synthesis by binding with high affinity to penicillin‑binding proteins. This binding blocks the final transpeptidation step of peptidoglycan cross‑linking, leading to weakened cell walls, osmotic instability, and ultimately bacterial lysis. Its broad spectrum includes many Gram‑negative, Gram‑positive, and anaerobic organisms.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: may be watery and self‑limiting.
• Rash: skin erythema or mild pruritus.
• Headache: transient and usually resolves without intervention.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Injection site reactions: pain or erythema at the infusion site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Seizures: especially in patients with renal impairment or high doses.
• Renal impairment: acute kidney injury in susceptible individuals.
• Severe neutropenia: marked reduction in neutrophil count.
• Thrombocytopenia: low platelet levels increasing bleeding risk.

Before initiating therapy, consider the following precautions:

• Renal function: adjust dosage in patients with impaired renal clearance.
• Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactam antibiotics.
• Pregnancy: use only when the potential benefit justifies the potential risk to the fetus.
• Concomitant valproic acid: monitor for reduced valproate concentrations.
• Superinfection: watch for overgrowth of non‑susceptible organisms such as fungi or resistant bacteria.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several medicines; monitoring is advised.

Major Interactions (Avoid)

• Valproic acid: may lower plasma valproate levels, reducing seizure control.
• Probenecid: can increase meropenem concentrations, raising toxicity risk.
• Nephrotoxic agents: concurrent use may exacerbate renal damage.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may heighten risk of nephrotoxicity.
• Aminoglycosides: additive renal toxicity potential.
• Anticoagulants: may potentiate anticoagulant effect, requiring INR monitoring.